Abstract Library

#2956 Somatostatin Analogs: The Economic Value of Lanreotide Autogel Delivery Attributes in the Treatment of GEP-NET versus Octreotide LAR – A UK Budget Impact Analysis

Introduction: Lanreotide autogel (LAN) and octreotide long acting release (OCT) are long-acting somatostatin analogues (LA-SSAs) used to treat patients (pts) with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). However, the treatments differ in terms of injection route, need for administration by a health care professional and dosing interval.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Feuilly M

Authors: Feuilly M, Cristeau O, Clay E, François C, Whalen J,

Keywords: somatostatin analogues, economics,

#1795 Results from a Phase 2, Open-Label, Multicenter, Randomized Study of the Novel, Octreotide (Oct) Subcutaneous (SC) Depot Formulation in Patients with Functioning Neuroendocrine Tumors (NETs) and Acromegaly Previously Treated with Long-Acting Octreotide

Introduction: Oct sc depot is a novel, ready to use formulation administered via a thin needle.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Pavel M, Borson-Chazot , Hörsch D, Lahner , Pivonello R,

Keywords: octreotide sc depot, NET,

#1534 Personalized 177Lu-Octreotate Peptide Receptor Radionuclide Therapy (PRRT) Allows a Safe and Significant Increase of Radiation Dose to Neuroendocrine Tumors (NETs)

Introduction: 177Lu-octreotate PRRT is commonly administered at fixed/empiric activity per cycle, which results in highly variable radiation doses to critical organs and undertreatment of the majority of patients.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Del Prete M, Buteau F, Beauregard J,

Keywords: personalized, PRRT, neuroendocrine tumors ,

#1317 Value of Octreoscan and 18FDG-PET for Clinical Prognosis of Patients with Neuroendocrine Neoplasms

Introduction: Despite the existence of biological markers of aggressiveness, the clinical course of gastro-entero-pancreatic (GEP) neuroendocrine neoplasms (NEN) remains difficult to predict. Discrepancies between imaging data generated with 111In-pentetreotide scintigraphy (SRS) and 18 F-FDG-PET could reflect the degree of cellular de-differentiation.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Gouffon M

Authors: Gouffon M, Prior J, Ratib O, Krause T, Pralong F,

Keywords: 111In-pentetreotide scintigraphy, 18F-FDG-PET, prognosis, clinical course,

#973 Toward a Preoperative Classification of Mesenteric Lymph Node Metastases for Better Selection of Carcinoid Tumors Before Radical Surgery

Introduction: Surgery for small bowel carcinoid (SBC) and lymph node (LN) metastases, when technically possible, represents the best therapy. However, surgical challenge is (i) not to recuse patients for false unresectable mesenteric artery invasion, and/or (ii) to avoid extensive small bowel resection.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Deguelte-Lardière S

Authors: Deguelte-Lardière S, Cadiot G, Appere F, Noaves M, Hentic O,

Keywords: carcinoid tumor, surgical procedures,